Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pavía, C.
Right arrow Articles by Vilaseca, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pavía, C.
Right arrow Articles by Vilaseca, M. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 24:970-971, 2001
© 2001 by the American Diabetes Association, Inc.

Letters: Comments and Responses
Letter

Plasma Homocysteine Levels in Type 1 Diabetic Patients

Carlos Pavía, MD, PHD1, Imma Ferrer, PHD2, Carme Valls, PHD2, Rafael Artuch, MD, PHD2, Catrina Colomé, PHD2 and M. Antònia Vilaseca, PHD2

1 Secció Endocrinologia, Unitat Integrada, Hospital Sant Joan de Déu–Clínic
2 Servei de Bioquímica, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain

We appreciate the comments of Cotellessa et al. (1) as well as their interest in our work. We agree on their results, which confirm our findings. In patients with type 1 diabetes, in the absence of serious complications, the plasmatic concentration of homocysteine is in the low range of the reference values for age-matched control subjects. For this reason, it does not seem to have a predictive role for angiopathy in these types of patients. On the other hand, in patients with type 2 diabetes, especially when signs of nephropathy or macroangiopathy coexist (2), hyperhomocystinemia is a usual finding. In a study carried out in a group of 19 type 1 diabetic adolescents (aged 14 to 18 years), those patients with microalbuminuria (defined as an index albumine/creatinine >3 mg/mmol) (Fig. 1) had basal plasma values of total homocysteine at 7.24 ± 1.62 µmol/l (mean ± SD). After a period of treatment (3–5 months) with captopril (50 mg/day), the microalbuminuria values returned to normal, whereas those of total homocysteine, 7.06 + 1.56 µmol/l, remained similar to those found in basal conditions. These results suggest that only in cases of impaired renal function (3) would an increase of plasma homocysteine take place as an indicator of subclinical atherosclerosis (4).



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1 — Multiple box-plot of plasma total homocysteine (tHcy, µmol/l), microalbuminuria (MA, mg/mmol creatinine), basal (B) versus posttreatment (T). Significant differences (Mann-Whitney U test) were observed only in MA (P < 0.0001).

 
The data obtained by Cotellessa et al. (1) as well as our results point to the fact that hyperhomocystinemia does not have a predictive value for the microangiopathy in patients with type 1 diabetes.

FOOTNOTES

Address correspondence and reprint requests to M. Antònia Vilaseca, Servei de Bioquímica, Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat (Barcelona), Spain.

References

  1. Cotellessa M, Minniti MS, Cerone R, Prigione F, Calevo MS, Lorini R: Low total plasma homocysteine concentrations (tHcy) in patients with type 1 diabetes. Diabetes Care 2001. In press
  2. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, Stehouwer CD, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22:125–132, 1999[Abstract/Free Full Text]
  3. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP: Hyperhomocystinemia in type 2 diabetes. Diabetes Care 23:1816–1822, 2000[Abstract/Free Full Text]
  4. Vermeulen EGJ, Stehouwer CDA, Twisk JWR, van den Berg M, de Jong SC, Mackaay AJC, van Campen CMC, Visser FC, Jakobs CAJM, Bulterijs EJ, Rauwerda JA: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progresión of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355:517–522, 2000[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pavía, C.
Right arrow Articles by Vilaseca, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pavía, C.
Right arrow Articles by Vilaseca, M. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum